Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 1, 2004, Pages 102-106

  Muramatsu, A ^a   Azuma, T ^a   Okajima, T ^a   Ohtani, M ^a   Dojo, M ^a   Yamazaki, Y ^a   Kuriyama, M ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 4344585688     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01983.x     Document Type: Conference Paper

References (21)

1. Stangheilini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999; 231 (Suppl.): 20-8.
2. Furukawa N, Iwakiri R, Koyama T, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol 1999; 34: 441-4.
3. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 1991 (Suppl.): 18-21.
4. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
5. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8.
6. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1988; 33: 1023-9.
7. Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-34.
8. Dupuy HJ. General well-being (PGWB). In: Wenger, NJ, Mattson, ME, Furberg, CD, Elinsson, J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. USA: Le Jacq Publishing Inc., 1984:170-83.
9. Inaba T, Kawai K, Kobara H, et al. The usefulness a structured questionnaire (QUEST) assessment of gastroesophageal reflux disease. J New Remedies Clinics 1999; 48: 1277-89 (in Japanese).
10. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
11. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 73-7.
12. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease. A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
13. Lauritsen K. Management of endoscopy-negative reflux disease: progress with short-term treatment. Aliment Pharmacol Ther 1997; 11 (Suppl. 2): 87-92.
14. Labenz J, Malfertheiner P. Hellcobacter pylori in gastro-oesophageal reflux disease: Causal agent, independent or protective factor? Gut 1997; 41: 277-80.
15. Haruma K, Hamada H, Mihara M, et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter 2000; 5: 24-9.
16. Oyasu K, Kiyota K, Inokuchi H, Habu Y, Sumitomo Y, Wakamatu T. The clinical evaluation of structured questionnaires for reflux esophagitis. Nippon Rinsho 2000; 58: 1832-7.
17. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
18. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996; 31 (Suppl, 221): 8-13.
19. Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol 1996; 31 (Suppl. 221): 14-7.
20. El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 181-5.
21. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.